3/13
11:35 am
cybn
Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]
Low
Report
Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]
3/13
07:50 am
cybn
Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
2/17
07:46 am
cybn
Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
Low
Report
Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
2/13
08:10 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.
2/12
08:52 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.
2/10
09:48 pm
cybn
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Low
Report
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
1/27
01:44 pm
cybn
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
1/22
01:39 pm
cybn
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Low
Report
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
1/15
12:07 pm
cybn
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Low
Report
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
1/13
07:30 am
cybn
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Medium
Report
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
1/9
05:00 pm
cybn
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Medium
Report
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025